Report of Foreign Issuer (6-k)
November 12 2015 - 7:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
November 12, 2015
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Trading
in Novo Nordisk shares by board members, executives and associated persons on 11 November 2015
Bagsvaerd, Denmark, 12 November 2015 In accordance with Section
28a of the Danish Securities Trading Act, the company’s board members and executives have given Novo Nordisk power of attorney
on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated
persons as reported by those persons to Novo Nordisk.
Please find below a statement of such trading in shares issued by Novo Nordisk.
Name |
Anne Marie Kverneland |
Reason for reporting |
Member of the Board of Directors |
Financial instrument and ID code |
Novo Nordisk B DK0060534915 |
Type of transaction |
Sale of shares |
Date of transaction |
11 November 2015 |
Place of transaction |
Nasdaq Copenhagen |
Volume of transaction |
265 shares |
Total value of transaction |
DKK 100,064 |
Page 2 of 3
Name |
Henrik Ehlers Wulff |
Reason for reporting |
Executive vice president, Product Supply |
Financial instrument and ID code |
Novo Nordisk B DK0060534915 |
Type of transaction |
Sale of shares |
Date of transaction |
11 November 2015 |
Place of transaction |
Nasdaq Copenhagen |
Volume of transaction |
2,800 shares |
Total value of transaction |
DKK 1,056,440 |
Definitions and background information:
Publication
Publication shall take place no later than two working days after the
trading by board members or executives or notification of trading by associated persons. Publication is only required when the
total amount of transactions of a specific board member/executive and his/her associated persons in any one calendar year has reached
5,000 euros.
Who are board members, executives and associated persons?
Board members and executives are members of the Board of Directors and
Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to
a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) relatives defined as brothers, sisters,
parents, grandparents etc, children, grandchildren etc who have shared the same household with a board member/executive for at
least one year, and 4) any legal person, including a company, a foundation or a partnership, which is controlled directly or indirectly
by a board member/executive and/or a person mentioned in 1)–3), or to which a board member/executive and/or a person mentioned
in 1)–3) has managerial responsibilities or economic interests substantially equivalent to the legal person.
What is trading/transaction?
Trading is any kind of transaction, including shares purchased
or otherwise acquired, shares sold or otherwise disposed, gifts, mortgages and grants and exercise of options, but not heritage.
Page 3 of 3
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq Copenhagen
and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US- based employees. The ID code
is the code (ISIN DK0060534915) of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place of transaction
is the actual place of transaction, ie Nasdaq Copenhagen or New York Stock Exchange.
What is volume and value of transaction?
The volume of transaction is the number of shares (of DKK 0.20 nominal
value) or other financial instruments traded. The transaction value is the number of shares traded multiplied by the transaction
price. The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction
value in DKK in case of ADRs listed on New York Stock Exchange.
Novo
Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has
given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia,
growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets
its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed
on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media: |
|
|
Anne Margrethe Hauge |
+45 3079 3450 |
amhg@novonordisk.com |
Ken Inchausti (US) |
+1 609 514 8316 |
kiau@novonordisk.com |
|
|
|
Investors: |
|
|
Peter Hugreffe Ankersen |
+45 3075 9085 |
phak@novonordisk.com |
Daniel Bohsen |
+45 3079 6376 |
dabo@novonordisk.com |
Melanie Raouzeos |
+45 3075 3479 |
mrz@novonordisk.com |
Kasper Veje |
+45 3079 8519 |
kpvj@novonordisk.com |
Frank Daniel Mersebach (US) |
+1 609 235 8567 |
fdni@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90 |
|
|
Company announcement No 70 / 2015 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: November 12, 2015 |
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer |
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Sep 2023 to Sep 2024